Combined tofacitinib citrate and 308-nm excimer laser treatment for vitiligo: a pilot study
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llae532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Jia Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, PR China. Hauptthemen laut MEDLINE: Vitiligo, Lasers, Excimer, Piperidines, Low-Level Light Therapy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Guangxi Zhuang Autonomous Region.
Abstract (Originalsprache)
Background
Vitiligo is a clinically prevalent acquired skin disorder characterized by depigmentation. Currently, the therapeutic options for vitiligo are restricted, and numerous issues exist, such as a prolonged treatment course, unsatisfactory therapeutic efficacy, adverse reactions and a high propensity for recurrence after treatment cessation.
Objectives
To assess the safety and efficacy of combined treatment involving oral tofacitinib citrate (TC) and a 308-nm excimer laser (EL), with the aim of discovering a rapid and effective treatment approach to minimize the side-effects of various drugs.
Methods
In total, 63 patients with progressive vitiligo and a Vitiligo Disease Activity Score of 4 from January 2022 to January 2024 were enrolled and divided into three groups. The three groups were: the TC combined with 308-nm EL and methylprednisolone treatment group (group 1); the TC and 308-nm EL treatment group (group 2); and the methylprednisolone alone treatment group (group 3). The treatment was continued for 24 weeks, and an assessment of therapy outcomes was performed.
Results
When TC was combined with 308-nm EL and methylprednisolone treatment (group 1), the effect was more rapid than in the other two groups. When TC was combined with 308-nm EL (group 2), it had a more favourable treatment effect than that of methylprednisolone alone (group 3), despite having a slower onset of effect. After 24 weeks of treatment, there was no significant difference between group 1 and group 2 in terms of the total response rate or significant response. However, when only methylprednisolone treatment was applied, the effect was relatively slow and ineffective.
Conclusions
This study confirmed a rapid and effective treatment of vitiligo was achieved through a combination of TC and 308-nm EL. No serious adverse reactions were reported, and therefore this could potentially offer an optimal treatment plan for patients with vitiligo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, PR China.
Förderung
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
Zitieren
APA
Gao, J., Li, Q., Huang, H., Yu, S., Qiu, Y., Liang, Y., Lan, L., & Li, L. (2025). Combined tofacitinib citrate and 308-nm excimer laser treatment for vitiligo: a pilot study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae532
Vancouver
Gao J, Li Q, Huang H, Yu S, Qiu Y, Liang Y, et al. Combined tofacitinib citrate and 308-nm excimer laser treatment for vitiligo: a pilot study. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llae532
BibTeX
@article{Gao2025,
author = {Gao, Jia and Li, Qiuting and Huang, Haiying and Yu, Siguang and Qiu, Yanping and Liang, Yanping and Lan, Lizhen and Li, Lili},
title = {Combined tofacitinib citrate and 308-nm excimer laser treatment for vitiligo: a pilot study},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llae532}
}
EUVIMED